Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: Results from the CanSeq study

Genetics in Medicine

Volumn 18, Issue 10, 2016, Pages 1011-1019

  Gray, Stacy W ^a,b,c   Park, Elyse R ^d   Najita, Julie ^a   Martins, Yolanda ^a   Traeger, Lara ^d   Bair, Elizabeth ^a   Gagne, Joshua ^a   Garber, Judy ^a,b,c   Jänne, Pasi A ^a,b,c   Lindeman, Neal ^b,c   Lowenstein, Carol ^a   Oliver, Nelly ^a   Sholl, Lynette ^b,c   Van Allen, Eliezer M ^a,b,c,e   Wagle, Nikhil ^a,b,c,e   Wood, Sam ^a   Garraway, Levi ^a,b,c,e   Joffe, Steven ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cancer; incidental findings; return of results; sequencing

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; FEMALE; GENE SEQUENCE; GENETIC SCREENING; GERMLINE MUTATION; HUMAN; INCIDENTAL FINDING; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONCOLOGIST; PATIENT ATTITUDE; PROSPECTIVE STUDY; AGED; EXOME; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; NEOPLASMS; PATHOPHYSIOLOGY; PROGNOSIS;

AGED; EXOME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; NEOPLASMS; ONCOLOGISTS; PROGNOSIS;

EID: 84989856761     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2015.207     Document Type: Article

References (41)

1. Green RC, Berg JS, Grody WW, et al.; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565-574.
2. Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: genetic and genomic testing for cancer susceptibility. J Clin Oncol e-pub ahead of print 31 August 2015.
3. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615.
4. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-975.
5. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-1525.
6. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-834.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
8. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
9. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
10. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
11. MacConaill LE, Garcia E, Shivdasani P, et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn 2014;16:660-672.
12. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015;17:251-264.
13. Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. J Clin Oncol 2013;31:1825-1833.
14. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-Throughput sequencing: a pilot study. Sci Transl Med 2011;3:111ra121.
15. Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol 2014;32:687-698.
16. Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians? attitudes about multiplex tumor genomic testing. J Clin Oncol 2014;32:1317-1323.
17. Nippert I, Harris HJ, Julian-Reynier C, et al. Confidence of primary care physicians in their ability to carry out basic medical genetic tasks-A European survey in five countries-part 1. J Community Genet 2011;2:1-11.
18. Michie S, di Lorenzo E, Lane R, Armstrong K, Sanderson S. Genetic information leaflets: influencing attitudes towards genetic testing. Genet Med 2004;6:219-225.
19. Sanderson SC, Wardle J, Michie S. The effects of a genetic information leaflet on public attitudes towards genetic testing. Public Underst Sci 2005;14:213-224.
20. Singer E, Antonucci T, Van Hoewyk J. Racial and ethnic variations in knowledge and attitudes about genetic testing. Genet Test 2004;8:31-43.
21. Furr LA, Kelly SE. The Genetic Knowledge Index: developing a standard measure of genetic knowledge. Genet Test 1999;3:193-199.
22. Fagerlin A, Zikmund-Fisher BJ, Ubel PA, Jankovic A, Derry HA, Smith DM. Measuring numeracy without a math test: development of the Subjective Numeracy Scale. Med Decis Making 2007;27:672-680.
23. Chew LD, Griffin JM, Partin MR, et al. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med. 2008;23:561-566.
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
25. Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 2005;23:3552-3561.
26. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
27. Degner LF, Kristjanson LJ, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA 1997;277:1485-1492.
28. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-706.
29. NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®)Non-Small Cell LungCancer Version 3.2014. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Published 24 January 2014. Accessed 1 February 2014.
30. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer Version 2.2015. J Natl Compr Canc Netw 2014:1-143. http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed 16 September, 2015.
31. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014;20:682-688.
32. Ramoni RB, McGuire AL, Robinson JO, Morley DS, Plon SE, Joffe S. Experiences and attitudes of genome investigators regarding return of individual genetic test results. Genet Med 2013;15:882-887.
33. Sheehan M. The right to know and genetic testing. J Med Ethics 2015;41: 287-288.
34. Johnson JA Pharmacogenetics in clinical practice: how far have we come and where are we going?. Pharmacogenomics 2013;14:835-843
35. Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med 2011;13:987-995.
36. Relling MV, Gardner EE, Sandborn WJ, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89:387-391.
37. Center for Drug Evaluation, Research. Genomics-Table of Pharmacogenomic Biomarkers in Drug Labeling. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed 23 January 2015.
38. Parsons DW, Roy A, Plon SE, Roychowdhury S, Chinnaiyan AM. Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. J Clin Oncol 2014;32:2203-2205.
39. Parker BA, Schwaederlé M, Scur MD, et al. Breast cancer experience of the molecular tumor board at the University of California, San Diego Moores Cancer Center. J Oncol Pract 2015;11:442-449.
40. Green MJ, Peterson SK, Baker MW, et al. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. JAMA 2004;292: 442-452.
41. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K; American College of Medical Genetics and Genomics. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010;28:893-901.